{"entity":{"id":"nct06514508","kind":"trial","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","aka":[],"tldr":"A phase 3 trial of Motixafortide, Filgrastim in multiple myeloma, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting.","summary":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients is a phase 3 interventional study registered as NCT06514508 by Guangzhou Gloria Biosciences Co., Ltd., with 60 participants planned, started 2025-12-01 and due to reach its primary completion in 2026-09-11. Interventions recorded: Motixafortide+G-CSF, Placebo+G-CSF. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06514508","url":"https://clinicaltrials.gov/study/NCT06514508"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["motixafortide","filgrastim"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06514508","phase":"3","setting":"A Phase Ⅲ, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","enrolled":60,"outcomes":[]},"route":"/trials/nct06514508/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/"}]}}